Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. - Matulonis, Ursula A.; Vergote, Ignace; Moore, Kathleen N.; Martin, Lainie P.; Castro, Cesar M.; Gilbert, Lucy; Xia, Yu; Method, Michael; Stec, James; Birrer, Michael J.; O'Malley, David M. (Gynecologic Oncology, 2025)